To establish a practical monitoring system of human herpesviruses reactivation in patients undergoing stem cell transplantation, we developed a new, very rapid, highly sensitive, and quantitative PCR assay for accurate measurement of human cytomegalovirus (CMV), human herpesvirus 6 (HHV-6) and Epstein-Barr virus (EBV) DNA using LightCycler. The LightCycler system revealed that there was a linear correlation in the wide range of viral template DNA at the indicated number of PCR cycles. Peripheral blood cells were collected from 16 patients undergoing stem cell transplantation. The cut-off level of CMV and HHV-6 was assessed as 10 2 copies/g and that of EBV as 10 3 . High numbers of CMV genomes were detected in 3/13 patients after transplant, and reactivation of HHV-6 was frequently seen, whereas none of the patient showed an elevation of EBV genome copies until the end of the observation period. In the present study, the reactivation of ␤ herpesviruses is associated with the occurrence of thrombotic microangiopathy (TMA) in two patients undergoing allogeneic BMT. Therefore, it may contribute in clarifying the pathological potential of human herpesviruses using a large number of clinical samples. Our results suggest that this system may be useful for monitoring viral reactivation. Bone Marrow Transplantation (2001) 28, 975-980.
SCT. 3 Human herpesvirus 6 (HHV-6) is classified into the same subfamily as CMV and ␤ herpesvirus. It has been linked to poor marrow engraftment, 4 encephalitis 5 and interstitial pneumonia, 6 although asymptomatic reactivation of HHV-6 is more common following SCT. 7 Epstein-Barr virus (EBV) is not a major cause of mortality after SCT. However, primary EBV infection and lymphoproliferative disorders may occur after T cell-depleted bone marrow transplantation (BMT). 8 These herpesviruses are also known to be associated with transplant-related complications such as graft-versus-host disease (GVHD) and delayed engraftment. 2 To date, one of the most sensitive approaches for the detection of human herpesviruses has been the polymerase chain reaction (PCR) method. PCR provides a specific technique for investigating disease association. However, the qualitative PCR method is insufficient to determine clinically relevant viral replications. Since the amount of viral DNA may vary between persistence in normal individuals and during primary infections or episodes of reactivation, and may be higher in immunocompromised patients, a quantification system for clinical samples is required. We have established a rapid real-time PCR system by fluorogenic hybridization probe and capillary PCR using a LightCycler.
In order to monitor the reactivation of three lymphotropic herpesviruses, namely CMV, HHV-6 and EBV in SCT recipients, we have developed a practical diagnostic quantification system using a LightCycler.
Materials and methods

Patients
Sixteen patients (median 28 years; range 17-55 years of age; 12 males and four females) undergoing SCT at Tokyo Medical University Hospital between 16 October 1998 and 20 October 2000 were enrolled ( Table 1 ). The median duration of follow-up was 180 days (range 90-730 days). Three patients died during the study. Four of the 16 patients were CMV seronegative before transplantation and received a graft from a CMV-negative donor. In the remain- auto-PBSCT MCNU/CBDCA/ETP/L-PAM AML = acute myeloid leukemia; MDS = myelodysplastic syndrome; RAEB = refractory anemia with an excess of blast; CML = chronic myeloid leukemia; ALL = acute lymphoblastic leukemia; NHL = non-Hodgkin's lymphoma; DL = diffuse large cell type; FL = follicular large cell type; ALCL = anaplastic large cell lymphoma; BMT = bone marrow transplantation; PBSCT = peripheral blood stem cell transplantation; TBI = total body irradiation; CY = cyclophosphamide; Ara-C = cytosine arabinoside; ETP = etoposide; MCNU = ranimustine; CBDCA = carboplatin; L-PAM = melphalan.
ing 12 patients, either the donor or the patient or both were seropositive. Oral acyclovir (1000 mg, four times, daily) was given to all patients after transplant up to 90 days. Ganciclovir (GCV) was delivered intravenously at a dose of 5 mg/kg (twice daily) to patient 2 from days 21 to 46 because of CMV interstitial pneumonia (CMV-IP). GCV was also given intravenously at a dose of 5 mg/kg (1ෂ2 times, daily) in two other patients where transient CMV antigenemia was detected. All samples were acquired after informed consent had been obtained.
Sample processing
Peripheral blood (1 ml, EDTA-N 2 M treated) was collected once before transplant and once per week after transplant for up to 8-24 weeks. For PCR analysis, DNA was extracted from whole blood cells using the DNA extraction WB kit (Wako Pure Chemical Industries, Osaka, Japan) as reported previously. 9 The DNA pellet was finally resuspended in TE buffer (10 mm Tris-HCl, pH 8.0; 10 mm EDTA). 0.1 g of purified DNA was used for each PCR assay.
Oligonucleotides
Primers and fluorescence labelled probes are shown in Table 2 . Melting temperatures (Tm) were calculated by using the TM Utility Program (Roche Molecular Biochemicals, Mannheim, Germany). For HHV-6 subtyping, the nested PCR was done as reported previously. 10 
LightCycler PCR assay
Real-Time PCR was done using a LightCycler DNA Master Hybridization Probes kit (Roche Molecular Biochemicals) according to the supplier's instructions. The total reaction volume was 20 l containing 2.8 mm MgCl 2 , 0.5 mm of Table 2 Oligonucleotides used in this study For standardization of the number of HHV-6 genomes, we used the target viral DNA cloned in a plasmid pUC19 as a reference. The amount of the reference was determined by either measurement of OD or competitive PCR using the competitive DNA construct kit (Takara, Shiga, Japan). 10 A serial dilution of the reference was used as a standard of the viral DNA number. Similarly, we used a plasmid containing the major immediate-early (MIE) gene region of HCMV: for plasmid construction, the corresponding sequence of the immediate-early gene region was inserted into a TA-Cloning Vector (Invitrogen, San Diego, CA, USA). 11 For EBV quantification, we used Raji cells that contain 50 copies/cell. 12 A serial dilution of the reference was used as standard of the viral DNA number. The estimation of viral genomes in each sample was arbitrarily expressed as the number of viral genomes per 1 g of purified DNA. Experiments were carried out at least twice to improve reliability of the results.
In this study, we prospectively performed and compared both the real-time PCR and pp65 antigenemia assay.
Statistical analysis
Comparison between two groups was analyzed using the chi-square test. Values of P Ͻ 0.05 were considered to be below statistical significance. The statistical tests were performed using Microsoftword Excell (Brain Power, Calabashes, CA, USA) software package for Macintosh personal computers.
Results
Quantification of CMV, HHV-6 and EBV in peripheral blood obtained from healthy volunteers
The validity of the real-time PCR using a LightCycler method was tested in a series of amplification experiments performed by serial dilutions of the reference. To generate the standard curve, we amplified the reference of at least seven concentrations for 10 0 to 10 6 molecules of template DNA. At the number of cycles indicated, there was a linear correlation in the wide range of reference (Figure 1 ). The amounts of viral DNA were calculated by using this standard curve. In order to determine viral load in clinical materials detected by real-time PCR, we first looked at the actual numbers of viral DNA in blood samples taken from 
Figure 1
The standard curve for quantification of the CMV viral template by LightCycler. In the range of 10 2 to 10 6 molecules of reference, there is a linear correlation (r = −1.0).
Table 3
Quantification of CMV, HHV-6 and EBV in peripheral blood obtained from healthy volunteers 52 healthy volunteers (Table 3 ). Based on the results obtained from healthy volunteers, we assessed the cut-off level of CMV and HHV-6 as 10 2 copies/g and that of EBV as 10 3 .
CMV viral load in SCT patients
The clinical time course and CMV viral load of 16 patients who underwent SCT are shown in Figure 2 . CMV copy numbers measured by real-time PCR were expressed per g of DNA extracted from the peripheral blood. CMV in 13 of the 16 patients could not be detected before transplant; however, high numbers of CMV genomes were detected in 3/13 patients after transplant. In patient 2, an elevation of CMV was seen together with CMV-IP ( patient died of sepsis possibly due to Corynebacterium sp. on day 95. In all cases, the results of real-time PCR and pp65 analysis were almost parallel throughout each patient's course.
HHV-6 viral load in SCT patients
In contrast to CMV, a reactivation of HHV-6 was frequently seen in patients who underwent SCT. A relationship between clinical symptoms and viral load was suggested in some allogeneic SCT patients, whereas none of the autologous SCT patients showed symptomatic HHV-6 reactivation ( Figure 3 ). Skin rash, the most common clinical symptom of HHV-6 reactivation was seen in patients 1, 6, 7 and 9 ( Figure 3a1, d , e, f). However, a diagnosis of GVHD was made only in patient 7. In the remaining three patients, skin biopsy specimens showed no evidence of GVHD. In patient 1, the HHV-6 number was again elevated during the sixth week, and was then diagnosed as TMA (Figure 3 a2 ). In patient 2, an elevation of HHV-6 genome copies occurred together with Hepatitis B virus reactivation ( Figure 3b ). Levels of HHV-6 copy numbers continued to be high up to 56 days in patient 5, and persistent thrombocytopenia was seen in this patient (Figure 3c ). The positive predictive value for symptomatic HHV-6 disease in allogeneic SCT patients calculated by the chi-square test was Ͻ0.001 ( 2 = 24.021). Unfortunately, we could not perform statistical analysis of positive and negative predictive value for HHV-6 disease in autologous SCT, since the number of cases analyzed in the current study is too small. Our system could detect either HHV-6A or HHV-6B. However, none of the patient with clinical symptoms showed the HHV-6A genotype detected by the nested PCR. Of note is that a reactivation of ␤ herpesviruses was found when TMA occurred in two allogeneic BMT patients (Table 4) .
EBV viral load in SCT patients
Before SCT, EBV could not be detected in 10 of the 16 patients, and 10 0.54 to 10 2.9 copies/g of EBV were detectable in the remaining six patients. During the course of SCT, eight of the 16 patients showed an elevation in EBV ranging from 10 1.36 to 10 2.75 . However, none of the patients showed an elevation of EBV genome copies to more than the cut-off level until the end of the observation period.
Discussion
Viral infections are important courses of morbidity and mortality after SCT. 1 To date, viral reactivation after SCT has been documented using PCR-based assays. However, qualitative PCR assay is insufficient to estimate active viral replication, 2-7 since herpesviruses latently infect most individuals and become reactivated when the immune system is impaired. Several methods for quantitative PCR have been reported, including end-point dilution of the template DNA, quantification using external and internal standards, and hybridization of PCR products to probes in a microwell format (PCR-ELISA). 10 The last two methods are considered to be the most accurate methods for quantification and have been applied to many viral detection systems. However, these tests are labor-intensive and require post-PCR handling. Using our LightCycler PCR system, all the procedures of amplification and quantification could be done in a single step with a wide dynamic range. Our system is therefore useful to monitor kinetics of herpesviruses in clinical practice.
The impact of viral infections on outcome in patients is directly dependent on the immune defect produced by a particular type of transplant. Maeda et al 13 have reported that the incidence of herpesviruses is lower in allogeneic peripheral SCT compared to allogeneic bone marrow transplantation possibly due to more rapid immune reconstitution after transplantation. More recently, Kimura et al reported a monitoring system of herpesviruses in unrelated cord blood transplantation. Since cord blood contains a few memory T cells to exogenous antigens, cord blood recipients may have a higher risk of infection: CMV and HHV-6 infections were found in all three patients analyzed.
14 In the current study, the reactivation of either CMV or HHV-6 associated with clinical symptoms is seen in allogeneic bone marrow transplant patients, while asymptomatic reactivation of HHV-6 is also seen in autologous peripheral blood transplantation. Taken together with the current observation, the kinetics of human ␤ herpesviruses appear to be a parameter of reconstitution of the host immune system and via versa. CMV-IP is a life-threatening infection after SCT. 3 In the current study, we identified a patient with CMV-IP. In this patient, both pp65 analysis and copy numbers of CMV were almost parallel. Unfortunately, we did not have a chance to analyze bronchoalveolar lavage fluid (BALF), since BALF analysis may be a helpful approach in predicting CMV-IP, as reported by others. 15 GVHD is also one of the serious complications after SCT. 16 We found two patients with GVHD. A skin rash is likely to be related to reactivation of HHV-6 in patients with GVHD. The one remaining patient did not show any ␤ herpesviruses reactivation. It is difficult to draw a final conclusion as to whether HHV-6 reactivation is a pathogen associated with GVHD or not, since we have only analyzed a limited numbers of patients.
It is noteworthy that a reactivation of human ␤ herpesviruses accompanied by TMA was seen in two patients in the intermediate post-transplant phase. TMA is one of the serious complications after SCT, 17 and clinical features of TMA are neurological disturbances, microangiopathic hemolytic anemia, renal failure and thrombocytopenia characterized by a common pathology of vascular endothelial cell damage and platelet aggregation. 17 Matsuda et al 18 have reported a case of thrombotic microangiopathy and suggested a possible association between endothelial cell damage and HHV-6 reactivation. GVHD, irradiation, high-dose chemotherapy, GVHD prophylaxis and viral infections such as herpesviruses 17 might cause vascular endothelial cell damage. Although it difficult to define an association of a virus with a particular clinical feature in these very complex medical cases in the current study, both HHV-6 and CMV appear to be disease-aggravating factors for TMA. Recently, several reports dealing with CMV and HHV-6 have demonstrated an efficient propagation of these herpesviruses in vascular endothelial cells in vitro. [19] [20] [21] [22] [23] In the present study, one patient with severe TMA (grade 4) showed an elevation of CMV genomes, while the other patient with mild TMA (grade 2) had HHV-6 reactivation. It is likely that pathological potential may differ between types of ␤ herpesviruses. The reactivation of ␤ herpesviruses with endothelial tropism may play an important role in the pathogenesis and development of TMA. Although some patients had a reactivation of ␤ herpesviruses, unknown factors that facilitate endothelial cell damage might exist, since not all patients with reactivation developed TMA.
In the present study, we found a patient with prolonged thrombocytopenia and an elevation of HHV-6 genomes until day 56. High levels of HHV-6 in the peripheral blood may correlate with delayed platelet engraftment, as reported by others. 4, 24 Isomura et al 25 also reported that the direct effect of HHV-6 on hematopoietic progenitors is one of the major causes of suppression of thrombopoiesis. To date, Bone Marrow Transplantation the pathogenic potential of HHV-6 in SCT recipients is not fully understood. This is mainly due to the difficulty in evaluating results, since HHV-6 reactivation is frequently seen in post-SCT recipients with or without clinical symptoms. In addition, HHV-6 viral load is analyzed in each laboratory by different types of PCR-based assay using either cell fraction or cell-free fraction. 7, 9, 13, 14, 24, 26, 27 Our quantification system is quite a simple procedure and does not require post-PCR handling and may therefore be useful in clarifying the pathological potential of HHV-6 using a large number of clinical samples.
During the observation period we could not find any EBV-related disease. Since post-transplant EBV-induced lymphoproliferative disorders (PT-LPD) may arise in the period between the initiation of engraftment and 6-8 mouths post transplant, at which time many patients have defects in T cell function, 4 we should keep following-up all the patients carefully.
Some investigators have shown that the detection of cellfree DNA by PCR in plasma might be more useful for discriminating between active infection and the latent stage, because particles of herpesviruses are released after proliferating in the case of active symptomatic infection. [27] [28] [29] In cases of qualitative PCR, PCR using the cell-free fraction is more reliable, since it is impossible to distinguish between latent stage and viral shedding using the cell fraction. However, our quantitative PCR system using the cell fraction can distinguish latent stage and active viral replication, even in pre-clinical stages. In addition, quantitative PCR using peripheral blood cells is the most sensitive for predicting lymphoproliferative disorders (PTLPD) after SCT, because PTLPD originates in the tumorous proliferations by division of EBV-infected B cell. Orii et al 30 reported that quantitative PCR using peripheral blood cells is the most sensitive method of predicting active viral replication after liver transplantation. Therefore, we concluded that it might be more predictive when run on peripheral blood cells using LightCycler.
Although the number of cases analyzed in this study is small, our results suggest that a measurement of copy number of herpesviruses using the real-time PCR system may be useful not only for monitoring viral reactivation but also for establishing new innovative preventive and therapeutic strategies for herpesviruses.
